cfDNA originates from apoptotic or necrotic cells and serves as an important biomarker for cellular damage, while ctDNA is derived from cancer cells undergoing apoptosis or necrosis and may contain cancer-specific gene mutations, such as KRAS (21). This evidence concerns the gene KRAS and cancer.